Pirinixil is an ethanolamine derivative of Wy-14,643 [4-chloro-6-(2,3-xylidino)-2-pyrimidinythio]acetic acid. It is the hypolipidemic agent of low toxicity. It has been reported to increase high density lipoprotein cholesterol levels in experimental animals. Pirinixil increased plasma cholesterol levels significantly without affecting plasma triglycerides. Pirinixil exerted a powerful antilipolytic activity against epinephrine, ACTH, nicotine and cold exposure. It is a potent inducer of liver peroxisones and of mitochondrial carmitine acetyltransferase. Pirinixil was developed treatment of hyperlipidemias and atherosclerosis. Pirinixil can increase generation of ROS, leading to DNA damage and p53 phosphorylation, which, in turn, induces the activation of Bax, release of cytochrome-c from mitochondria and activation of caspases, culminating in rat hepatoma FaO cell death.